SUMMARY pRB-family pocket proteins consisting of pRB, pI07, and pI30 are thought to act as a set of growth regulators that inhibit the cell-cycle transition from G 1-to S-phases by virtue of their interaction with E2F transcription factors. When cells are committed to progressing through the cell-cycle at the late GI restriction point, they are hyperphosphorylated by G 1 cyclin-cyclin dependent kinase (CDK) and are functionally inactivated.
INTRODUCTION
The decision to commit to cell di vision takes place at a late G 1 point, termed the restriction point, that precedes the onset of DNA synthesis in the S-phase. The passage through the restriction point is primarily controlled by the retinoblastoma protein (pRB)1 family, which consists of pRB, pl07, and p130 (1) (2) (3) (4) . The pRB-family proteins, acting as negative growth regulators, share a structure termed the "pocket domain" and, through the domain, interact with multiple cellular proteins, most notably the E2F family of transcriptional factors (4) (5) (6) . E2Fs transactivate a set of genes whose products are critical in S-phase entry and progression (5) (6) (7) (8) . Upon complex formation, pRB-family proteins neutralize the transcriptional activities of E2Fs (4, 6, 9, 10) . Furthermore, the pRB-family-E2F complexes appear to also act as E2F site-specific transcriptional repressors (6, (11) (12) (13) . Hence, by actively repressing E2F-dependent gene expression, the pRB-family proteins prevent cell-cycle progression from Gl to S.
The pocket function of the pRB-family proteins is considered to be negatively regulated by phosphorylation (14) (15) (16) (17) (18) (19) (20) (21) (22) . Upon mitogenic stimulation, G 1 cyclin-cyclin dependent kinase (CDK) complexes are activated and collaboratively phosphorylate the pRB-family proteins (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) .
Through extensive phosphorylation, the pRB-family proteins lose their ability to form complexes with E2Fs, and the released E2Fs initiate S-phase entry and subsequent progression (4, 8, 14, 30) . Accordingly, inactivation of the pRB-family proteins appears to be an essential prerequisite for traversing the restriction point.
Ectopic expression of pRB-family proteins III a variety of cell types gives rise to Gl cell-cycle arrest (31) (32) (33) (34) (35) , supporting their crucial roles in preventing S-phase entry. Consistently, pRB and p130 are abundantly expressed in GO/G I-arrested cells in their acti ve, hypophosphorylated forms (4, 19, 20, 36) . In contrast, the pl07 protein levels are modulated in an opposing manner. In quiescent cells, pl07 protein levels are very low, which is at least in part due to E2F-dependent transcriptional repression of the pi07 gene, most probably through the pRB-E2F and/or p130-E2F repressor complex (4, 37) . As cells progress toward mid-to-Iate Gl, the levels of pl07 increase, and in S-phase cells pI 07 becomes a predominant pocket protein, although the majority are hyperphosphorylated and hence inactivated (4, 19, 37) . These results indicate that low levels of pI 07 present during mid-to late G 1 may play an important role in traversing the restriction point in conjunction with other pocket proteins. Alternatively, pl07 may playa unique role among the pocket proteins in cells that have already passed the G I restriction point.
We have previously shown that in certain hematopoietic cells, including BaF3 and 32D cells, ectopically expressed p 130 inhibits the cellcycle in G 1, whereas pRB, even in its phosphorylation-resistant form, fails to do so (34, 38) . Given this observation, we wished to know the role of pl07, which is structurally closer to pI30 than pRB (4) , in hematopoietic cellcycle regulation. We therefore generated BaF3 lymphoid cells in which wild-type or a non-phosphorylatable and thus constitutively active pI07 was inducibly expressed. Here we demonstrate that pI 07 is capable of inhibiting the S-phase cell-cycle progression. We further provide evidence that pI07 is involved in inhibiting the cell-cycle in S-phase cells with DNA damage.
MATERIALS AND METHODS
Construction of Plasmids -A pI07 mutant, pl07~S/T-P, which lacks all of the potential phosphorylation sites by cyclin-CDK was generated from human pI 07 cDN A by multiple rounds of oligonucleotide-mediated mutagenesis with use of Chameleon site-directed mutagenesis system (Stratagene) according to the manufacturer's instructions (22). In this mutant, threonines-332, -340, -369, -385, -915, -997, serines-368, -515, -615, -640, -650, -749, -762, -964, -975, -988, -1009, and -1041 were substituted with alanine residues. Wild-type and the phosphorylation-resistant pI 07
were tagged with influenza hemagglutinin (HA) epitope at the carboxy terminus (p 1 07HA and pI 07 ~S/T -P-HA). cDNAs encoding pI 07HA and pI 07 ~S/T -P-HA were inserted into a mammalian expression vector, pSP65SRa2 (39) . pOPTET-BSD IS an inducible cDNA expression vector having the TcIP promoter and the blasticidin-resistance gene as a drugselection marker (34, 40) . A cDNA encoding pI07HA, pl07~S/T-P-HA or adenovirus E 1 A 12S (E 1 A) was sub cloned into the pOPTET -BSD vector.
Cell Culture -COS-7 and SAOS-2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). The 6-1 cell is a BaF3-derived mouse pro-B cell line that stably co-express tTA and LacI (34, 40, 41) . Cells were cultured in RPMI1640 medium containi ng 1090 FCS and 2090 WEHI-3B-conditioned medium (2090 WEHI) as a source of interleukin 3 (IL-3). Stable transfectants that conditionally express p107HA, p107L'lS/T-P-HA or E1A were created by transfecting pOPTET -BSD-p 1 07HA, pOPTET -BSD-p 1 07 L'lS/T -P-HA or pOPTET-BSD-E1A into 6-1 cells by electroporation as described (34, 38) .
Expression of the cDNA-directed proteins in these transfectants was repressed in medium containing 1 /lg/ml tetracycline (Tc) and was induced in medium containing 5 mM isopropyl ~-D-thiogalactopyranoside (IPTG) for 24 h in the absence of Tc.
Immulloprecipitation and Immu/loblot Analysis -COS-7 cells in a 1 OO-mm plate were transfected with 10 /lg of each expression plasmid using the DEAE-dextran method. SAOS-2 cells in a 100-mm plate were transfected with 20 /lg of each expression plasmid using the calcium-phosphate precipitation method. The transfected cells were harvested 2 days after transfection, and lysed in ELB buffer (250 mM NaCl, 5 mM EDT A, 50 mM HEPES, pH 7.0, 0.5% Nonidet P-40, 10 /lg/mlleupeptin, 10 /lg/ml aprotinin, 10 /lg/ml trypsine inhibitor, 0.5 /lM DTT and 1 mM phenylmethylsulfonyl fluoride (PMSF) (32 
RESULTS

Effect of the Phosphorylation-Resistant pi07 Oll the Hematopoietic
Cell-cycle 6-1 cell is a BaF3-derived mouse lymphoid cell line whose growth is totally dependent on interleukin 3 (IL-3), with the depletion of IL-3 24 h from the start of culture inducing GO/G 1 cell-cycle arrest ( Fig. 1 A, o h). In these growth-arrested 6-1 cells, a member of pRB family, p 130, was abundantly expressed whereas expression of pI 07 was very low ( Fig. 1 A) . By this time point, p 130 became barely detectable, whereas pi 07 was potently induced and abundantly expressed but was hyperphosphorylated (Fig. IB, lane 3) . Twenty-four h after IL-3 stimulation, the cell-cycle profile returned to the pattern that is typical of asynchronously growing cells (Fig. 1 A) .
Using this cell-cycle re-entry/progression protocol, we wished to address the possible role of pI 07 in cell-cycle regulation, particularly in Sphase progression. As an initial approach, we generated 6-I-deribed stable transfectants, pI07-13 and pI07-I6, that conditionally express wild-type pI07 ( Fig. 2A) with the use of the tetracycline/IPTG dual-regulated inducible system, in which expression of the cDN A is strongly inhibited by tetracycline and is potently activated by IPTG (34, 40) . However, despite ectopic pI07 expression (Fig. 2B ), we were not able to see any changes in the cell-cycle entry and progression in response to elevated pI07 ( Fig. 2C ).
This may be at least in part due to insufficient expression of ectopic pI07, as actively cycling 6-1 cells already express high levels of endogenous pI07
( Fig. IB) . Indeed, we could only increase the pI07 levels by at most two fold in relation to endogenous levels (Fig. 2B , compare the expression of total pI07 between Tc-and IPTG-treated lanes at the corresponding times).
Furthermore, the massive phosphorylation of pI 07 in response to IL-3 restimulation ( Fig. 2B) indicates that under such circumstances cells possess pI07 kinase activity that is sufficient to inactivate both endogenous and exogenous pI07.
Accordingly, we next generated a phosphorylation-resistant pI 07 mutant by replacing all of the serine and threonine residues that constitute possible cyclin-CDK phosphorylation motifs (either serine-proline or threonine-proline) with non-phosphorylatable alanine residues ( (Fig.5C ). In striking contrast, in the presence of p 1 07 ~S/T P-HA, DNA synthesis was severely impaired and most cells failed to achieve replication of full genome as late as 24 h (Fig. 5C) . These results clearly demonstrate that the phosphorylation-resistant pI 07 is capable of inhibiting progression of the S-phase. It should be noted, however, that the cells were obviously capable of initiating some degree of DNA synthesis in the presence of pI 07 ~S/T -P-HA although they failed to complete genome replication (Fig. 5C ). This may indicate that chain elongation can still take place in the presence of the phosphorylation-resistant p 1 07.
Although the phosphorylation-resistant pI 07 is capable of inhibiting S-phase progression, it remains possible that the S-phase inhibitory effect is due to supraphysiologic levels of the protein expressed. To address this possibility, we examined the expression levels of the pl07 mutant. Because pl07.6.S/T-P-HA is detectable exclusively in its hypophosphorylated form, it is possible to compare expression levels between endogenous pI 07 and pl07. 6 .S/T-P-HA. In the IPTG-treated PRp107-24 cells wherein pl07. 6 
.S/T-P-
HA was inducibly expressed ( cisplatin was added to the culture. Cell-cycle analysis revealed that the cisplatin treatment provoked a delay in S-phase entry that was followed by a severe inhibition of S-phase cell-cycle progression (Fig. 6A) , a change that is reminiscent of that observed with the cells expressing the phosphorylation-resistant pI 07 (see Fig. 4C and 5C). These results indicate that genotoxic stress such as DNA damage can inhibit S-phase cell-cycle progression. We also note that p53 and p2I proteins were upregulated within several hours after cisplatin treatment as reported previously ( Fig. 6B ) (39) .
We also examined the phosphorylation status of pl07 in cells treated with cisplatin. Whereas pI 07 was mostly hyperphosphorylated when cisplatin was added to the culture (8 h after IL-3 stimulation), the hypophosphorylated form of pI 07 reappeared at 16 h after IL-3 stimulation in the cisplatin-treated cells, but not in untreated cells, and increased thereafter (Fig. 6B, lanes 3, 6-8 ). This observation suggests that cell-cycle inhibition in S-phase cells is concomitantly associated with the reappearance and accumulation of hypophosphorylated pI 07.
The Effect of Ectopic p 107 all Cellular Responsiveness to Cisplatin -
To address the role of pI07 in S-phase cell-cycle inhibition in DNA damaged cells more directly, we employed the pI07-I6 cells that conditionally express HA-tagged, wild-type pI 07 under the control of the tetracycline/IPTG dual-regulation system (see Fig. 2A ). The pI07-16 cells were growth-arrested by IL-3 deprivation and then restimulated with IL-3.
During IL-3 starvation, pl07 was induced by IPTG (Fig. 2B ). As previously demonstrated in Fig. 2C , a simple induction of ectopic pI 07 did not significantly alter the cell-cycle profile of the 6-1 cells. However, following treatment with cisplatin at 8 h after IL-3 stimulation, pI07-induced cells exhibited a stronger inhibition of S-phase progression than that observed in pI 07 -uninduced cells (Fig. 7 A) . These results indicate that the cell-cycle inhibitory activity of cisplatin is proportional to the pl07 levels.
Intriguingly, in these cisplatin-treated cells, ectopic pI07 existed most exclusively in its hypophosphorylated form as late as 24 h after IL-3 stimulation (Fig. 7B, lane 10) . Because the HA-tagged pI07 is constitutively produced under the TcIP promoter in the transfectants, our results indicate that phosphorylation of pI07 may be inhibited in the DNA-damaged S-phase cells.
Effect of EIA Oncoprotein all the S-phase Inhibitory Effects of
Cisplatin -Adenovirus EIA protein is known to physically interact with and functionally inactivate pRB-family pocket proteins (43-46), including pI07 (33, 47, 48) . Accordingly, if pI07 is actively involved in the inhibition of S-phase cell-cycle progression in response to DNA damage, then EIA would be expected to counteract the cell-cycle inhibitory activity of cisplatin. To address this, we generated a 6-I-deri ved, stable transfectant, E I A 15-1, that ectopically expresses the EIA I2S product (Fig. 8A) . Expectedly, in the EIA transfectant cell, the E 1 A protein formed physical complexes with endogenous pI07 (Fig. 8B ). However, a simple overexpression of EIA did not provoke any significant change in IL-3-dependent growth in 6-1 cells 3 .
The parental and the E I A-expressing cells were then growth-arrested by IL-3 deprivation and were subjected to cisplatin treatment at 8 h after IL-3 restimulation. In cells expressing EIA, the S-phase inhibitory activity of cisplatin was significantly reduced and a relatively large fraction of cells was capable of exiting from S-phase within 32 h (Fig. 8, C It is therefore possible that, under certain cellular settings, the pRB-family pocket proteins may play an active role in post Gl cell-cycle regulation.
The expression levels of pRB are relatively constant throughout the cell-cycle (4, 19) . In contrast, the levels of 107 and p130 proteins change dramatically as cells progress through the cell-cycle. p 130 is abundantly present III quiescent cells and, upon mitogenic stimulation, it is hyperphosphorylated in mid to late G I-phase. The p 130 protein levels are then progressively downregulated as cells move into S-phase (4, 20, 36) . In contrast, the levels of pI 07 are regulated in a manner opposite to that observed for p130. In quiescent cells, pl07 expression is very low. As the cell-cycle progresses from the early to the midllate G I-phases, pI 07 begins to accumulate dramatically (4, 19) . This pl07 expression is primarily regulated at the transcriptional level (8) . In particular, reciprocal expression between pI 07 and p 130 can be explained at least in part by the E2F sites present in the promoter of the pI07 gene (37) . It has been suggested that the pI07 promoter is under the negative control of p130-E2F and/or pRB-E2F complex present in the quiescent cells. Increases in pI 07 levels as the cellcycle progresses from the quiescent state again suggests that the pocket protein might be able to regulate post-G 1 cells, rather than simply preventing S-phase entry.
We have previously shown that growth of hematopoietic cells such as BaF3 and 32D is strongly inhibited by ectopic expression of p130, but not by pRB, even in its phosphorylation-resistant form (34, 38) . In these cells, p130
prevents S-phase entry, at least in part, through inhibiting the transcriptional activity of E2F-4 (34). Because pl07 is more similar to p130 than pRB among the pRB -family pocket proteins (4, 53), we wished to determine the role of pl07 in the hematopoietic cell-cycle. As an initial approach, we generated 6-1 transfectants that conditionally express wild-type pI07 through the use of the Tc/IPTG dual-regulated, inducible promoter system (34, 40) . Because pI07 is a relatively abundant protein in cycling cells, we could only increase the cellular pI 07 levels at most by two fold upon induction. Under this condition, we were not able to observe any changes in IL-3-dependent cell-cycle entry and progression by the elevated pl07.
Possibly, the amounts of ectopic pI 07 expressed were not sufficient to exert biological activities. Alternatively, pI07 might be much more sensitive to Gl cyclin-CDK than pRB and p130, and may be instantly inactivated during G I progression. If the latter is correct, then we can conclude that pI 07 does not playa major role in G I cell-cycle regulation.
To pursue further the possible role of pI 07 in cell-growth regulation, we generated in this work a novel pI 07 molecule that is completely resistant to cyclin-CDK mediated phosphorylationlinactivation. Upon its inducible expression in the BaF3-deri ved cells, we observed two distinct effects of the phosphorylation-resistant pI 07 in cell-cycle regulation. First, the phosphorylation-resistant pI 07 is capable of retarding the G I-to-S transition. The molecular mechanisms through which pI 07 or pRB inhibits Sphase progression is currently unknown. In the case of pRB, the S-phase response is suggested to involve origin-activation machineries (65) . As is the case of pRB, the early-S-phase-synchronized cells were capable of initiating some degree of DNA synthesis but were incapable of full genome replication in the presence of phosphorylation-resistant pI 07. This finding is consistent with the idea that pI07 inhibits the origin activation process rather than the DNA elongation process (66) . In this regard, it has been recently reported that pRB family proteins (pRB, pI07, and p130) can bind MCM7, a component of pre-replication complex (pre-RC), and inhibit in vitro DNA replication in an MCM7-dependent manner (65) . It is therefore intriguing to speculate that hypophosphorylated pI 07 is capable of inhibiting origin activation by directly interacting with MCM or the related pre-RC components. Indeed, pRB family members are associated with early S-phase replication sites (67) . Alternatively, pI07 may inhibit S-phase progression through transcriptional control because ORC I and CDC6 genes, whose products are also essential components of pre-RC, are transcriptionally activated by E2F, the critical target of the pRB family proteins (68, 69) .
The involvement of pI07 in S-phase cell-cycle arrest in response to DNA damage indicates that its functional loss may provoke abnormal cellcycle progression that is concomitantly associated with genetic instability.
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